271 related articles for article (PubMed ID: 27878567)
1. Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
Zhu T; Parker B; Wojtkowski T; Nishimura T; Garg JP; Han D; Fisniku O; Keirns J
Clin Pharmacokinet; 2017 Jul; 56(7):747-757. PubMed ID: 27878567
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Zhu T; Howieson C; Wojtkowski T; Garg JP; Han D; Fisniku O; Keirns J
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):548-555. PubMed ID: 28301084
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
4. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
Cao YJ; Sawamoto T; Valluri U; Cho K; Lewand M; Swan S; Lasseter K; Matson M; Holman J; Keirns J; Zhu T
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):435-449. PubMed ID: 27162173
[TBL] [Abstract][Full Text] [Related]
7. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.
Gao X; He X; Oshima H; Miyatake D; Otsuka Y; Kato K; Cai C; Wojtkowski T; Song N; Kaneko Y; Shi A
Drug Des Devel Ther; 2022; 16():1365-1381. PubMed ID: 35586186
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Miyatake D; Shibata T; Shibata M; Kaneko Y; Oda K; Nishimura T; Katashima M; Sekino H; Furihata K; Urae A
Clin Drug Investig; 2020 Feb; 40(2):149-159. PubMed ID: 31729626
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Gidal BE; Mintzer S; Schwab M; Schutz R; Kharidia J; Blum D; Grinnell T; Sunkaraneni S
Epilepsy Res; 2017 Sep; 135():64-70. PubMed ID: 28624574
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
[TBL] [Abstract][Full Text] [Related]
13. The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Kiyota T; Kambayashi A; Nishimura T
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):283-290. PubMed ID: 32618438
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.
Roh H; Son H; Lee D; Chang H; Yun C; Park K
Clin Ther; 2014 Aug; 36(8):1159-70. PubMed ID: 25017182
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
[TBL] [Abstract][Full Text] [Related]
18. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Qiu Q; Feng Q; Tan X; Guo M
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
[No Abstract] [Full Text] [Related]
19. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Quinson AM; Haertter S
J Clin Pharmacol; 2017 Oct; 57(10):1305-1314. PubMed ID: 28513969
[TBL] [Abstract][Full Text] [Related]
20. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
